REDX — Redx Pharma Income Statement
0.000.00%
Last trade - 00:00- £35.01m
- £34.60m
- £4.20m
Annual income statement for Redx Pharma, fiscal year end - September 30th, GBP millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.13 | 5.68 | 10 | 18.7 | 4.2 |
| Cost of Revenue | |||||
| Gross Profit | 2.78 | — | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 9.38 | 13.9 | 29.8 | 35 | 38 |
| Operating Profit | -6.25 | -8.2 | -19.7 | -16.3 | -33.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.33 | -9.17 | -21.4 | -17.8 | -32.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.32 | -9.21 | -21.6 | -18 | -33.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.32 | -9.21 | -21.6 | -18 | -33.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.32 | -9.21 | -21.6 | -18 | -33.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.039 | -0.054 | -0.084 | -0.061 | -0.094 |